[Effect of adriamycin combined with 40 and 43 degrees C hyperthermia on cultured V79 cells and S-180 tumor and their uptake of the drug].
The combined effects of hyperthermia and chemotherapy with adriamycin (ADR) on both cultured mammalian cells and growing tumors were analyzed according to different temperatures and durations of heating, timing of drug administration, and fractionation of treatments. Furthermore, ADR uptake in tumor was measured to evaluate the effect of ADR in combination with hyperthermia. Hyperthermic cell killing with ADR in vitro was much more potent at 40 degrees C than at 43 degrees C. Results of sequential combinations heating followed by ADR and ADR followed by heating under hyperthermia of 40 and 43 degrees C were not significantly different from those of simultaneous treatment. However, the anti-tumor effect of the combination was much more pronounced at 43 degrees C than at 40 degrees C for up to 60 min of treatment. ADR uptake showed a substantial increase under high temperatures of 40 and 43 degrees C in both cultured cells and tumors. Fractionated treatments combined with chemotherapy and hyperthermia showed no enhanced effects on tumor under temperatures of 40 and 43 degrees C, since three fractionated experiments with ADR and 43 degrees C hyperthermia had an effect almost identical to that of three fractionated experiments with hyperthermia alone, suggesting the possible induction of thermotolerance by ADR. The results of the present study indicate that potentiation of the combined effect of hyperthermia and chemotherapy with ADR may depend only upon the dose in one of these two modalities.
Yoshida
M
M
Department of Radiology, Kansai Medical University.
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D003131:Combined Modality Therapy; D006224:Cricetinae; D004317:Doxorubicin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006979:Hyperthermia, Induced; D051379:Mice; D008813:Mice, Inbred ICR; D009368:Neoplasm Transplantation; D012510:Sarcoma 180 / Q000188:drug therapy / Q000378:metabolism / Q000628:therapy*
D004317:Doxorubicin